At Biolife genetics, I conduct site qualification, initiation, monitoring, and closeout visits for Phase I–IV studies in cardiovascular, metabolic, and oncology research. I improved clinical data query resolution by 35% through source data verification, EDC reviews, and structured follow-up.
I also reduced recurring protocol deviations by 30% through risk-based monitoring, site retraining, and CAPA follow-up. My work includes safety reporting and regulatory compliance under ICH-GCP, FDA requirements, and study protocols.
Previously, at Proclinical, I performed on-site and remote monitoring and supported study startup and site activation. Earlier, at Innovaderm, I handled biological samples and improved sample tracking accuracy by 35% using standardized labeling, electronic inventory spreadsheets, and barcode verification.
